Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.
Castillo-Mancilla JR, Morrow M, Hunt PW, Schnittman SR, Phillips AN, Baker JV, Haberer JE, Janeiro MJ, Aragao F, Cohen C, Musinguzi N, Brown TT, Cavassini M, Glass TR, Serrano-Villar S, Mawhinney S, Siedner M. Castillo-Mancilla JR, et al. Among authors: baker jv. Open Forum Infect Dis. 2023 May 3;10(5):ofad230. doi: 10.1093/ofid/ofad230. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37213424 Free PMC article.
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.
Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I; INSIGHT Study Group. Boulware DR, et al. Among authors: baker jv. J Infect Dis. 2011 Jun 1;203(11):1637-46. doi: 10.1093/infdis/jir134. J Infect Dis. 2011. PMID: 21592994 Free PMC article. Clinical Trial.
Factors associated with D-dimer levels in HIV-infected individuals.
Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Borges AH, et al. Among authors: baker jv. PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014. PLoS One. 2014. PMID: 24626096 Free PMC article.
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.
Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD; INSIGHT SMART/ESPRIT/SILCAAT Study Group. Grund B, et al. Among authors: baker jv. PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016. PLoS One. 2016. PMID: 27171281 Free PMC article.
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.
Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group. Baker JV, et al. J Am Heart Assoc. 2017 May 22;6(5):e004987. doi: 10.1161/JAHA.116.004987. J Am Heart Assoc. 2017. PMID: 28533305 Free PMC article. Clinical Trial.
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.
Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group. Ronit A, et al. Among authors: baker jv. J Infect Dis. 2018 Jan 17;217(3):405-412. doi: 10.1093/infdis/jix350. J Infect Dis. 2018. PMID: 29244111 Free PMC article. Clinical Trial.
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.
Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, Munderi P, Aho I, Emery S, Babiker A, Phillips A, Lundgren JD, Neaton JD, Lane HC; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group. Baker JV, et al. Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262. doi: 10.1093/ofid/ofx262. eCollection 2017 Fall. Open Forum Infect Dis. 2017. PMID: 29308409 Free PMC article.
The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy.
Sortino O, Hullsiek KH, Richards E, Rupert A, Schminke A, Tetekpor N, Quinones M, Prosser R, Schacker T, Sereti I, Baker JV. Sortino O, et al. Among authors: baker jv. J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042. J Infect Dis. 2019. PMID: 30721997 Free PMC article. Clinical Trial.
Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.
Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group. Castillo-Mancilla JR, et al. Among authors: baker jv. J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297. J Int AIDS Soc. 2019. PMID: 31250552 Free PMC article. Clinical Trial.
127 results